HRMY - Harmony Biosciences Holdings, Inc.
IEX Last Trade
34.07
-0.660 -1.937%
Share volume: 0
Last Updated: Fri 27 Dec 2024 03:30:05 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.05%
PREVIOUS CLOSE
CHG
CHG%
$34.73
-0.66
-1.90%
Fundamental analysis
76%
Profitability
83%
Dept financing
24%
Liquidity
75%
Performance
81%
Performance
5 Days
-2.55%
1 Month
-2.21%
3 Months
-14.40%
6 Months
9.59%
1 Year
2.96%
2 Year
-39.93%
Key data
Stock price
$34.07
DAY RANGE
N/A - N/A
52 WEEK RANGE
$28.98 - $41.61
52 WEEK CHANGE
$2.19
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: John C.s Jacobs
Region: US
Website: harmonybiosciences.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: harmonybiosciences.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Harmony Biosciences Holdings, Inc. develops and commercializes therapies for patients with rare neurological disorders in the United States. WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Recent news